Natalizumab   Fingolimod   P*   Fingolimod   P**           Without prior natalizumab exposure   With prior natalizumab exposure     Proportion of patients free from any disease activity 72.0% 59.1% 0.014 61.8% 51.7% 0.008   Proportion of patients free from MRI lesions 87.5% 70.0%   <0.001 74.5% 68.3% <0.001   Proportion of patients free from relapse 82.5% 81.3% 0.739 86.3% 68.2% 0.01   Proportion of patients free from EDSS progression 93.5% 89.6% 0.186 92.2% 82.5% 0.06

Table 2: Cumulative proportion of patients free from disease activity at 1-year follow-up (*Comparison between natalizumab and fingolimod groups; **Comparison between natalizumab, fingolimod without prior natalizumab exposure, and fingolimod with prior natalizumab exposure; EDSS-Expanded Disability Status Scale; MRI-Magnetic Resonance Imaging)